Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNausea is the most commonly reported side effect of Mounjaro (tirzepatide), particularly in the first few weeks of treatment or after a dose increase. Most people who feel sick on Mounjaro find it settles within a few days as the body adjusts — but knowing why it happens, and what genuinely helps, makes the experience a lot easier to manage. These are prescription-only medicines; a GPhC-registered prescriber assesses your suitability before any treatment starts, and they're the right person to contact if nausea becomes difficult to handle.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Mounjaro activates two gut-hormone pathways simultaneously: GLP-1 and GIP receptors. One of the direct consequences is that your stomach empties more slowly than usual. Food sits there longer, which is partly how the medicine reduces appetite, but it also means your digestive system needs time to recalibrate, and nausea is the most common signal that it is doing exactly that.
The sick feeling tends to be most noticeable at the start of treatment or in the first week or two after a dose step-up. That pattern is why treatment begins at 2.5mg: the opening dose exists to give your system a gentler introduction, not to produce therapeutic weight loss straight away. For most people, the nausea settles before the next dose change. The full side-effect profile of Mounjaro covers the wider picture if you want more context.
The NHS patient information page on tirzepatide lists nausea as a very common side effect, meaning it affects more than one in ten people. That framing is worth holding onto when it hits: you are not reacting badly to the medicine in an unusual way.
This is usually the real question. Feeling sick on Mounjaro after eating is unpleasant, and the temptation is either to stop eating entirely or to wonder whether the medicine is right for you at all. Neither response is usually necessary.
What the evidence and clinical experience consistently point to is that meal habits are the most controllable variable. Smaller portions eaten slowly, with lower fat content, make a substantial difference. Many people find the nausea is worse when they forget the medicine has already blunted hunger signals and they sit down to a normal-sized meal anyway. The stomach simply cannot process it at the usual pace. A look at why eating specifically triggers the sick feeling on Mounjaro can help you identify which habits to change first.
Staying upright for at least an hour after eating, keeping well hydrated between meals rather than with them, and avoiding alcohol in the early weeks are all practical steps that cost nothing. Fatigue often accompanies the nausea in those first weeks too, the connection between tiredness and tirzepatide is worth reading if that's part of your experience.
Mild to moderate nausea that comes and goes, particularly around doses or meals, does not usually require urgent attention. Persistent vomiting that stops you keeping fluids down is different. Dehydration can develop quickly, and that becomes a medical problem in its own right.
Seek prompt help if you have severe stomach pain that spreads to your back, with or without vomiting. In January 2026, the MHRA issued a Drug Safety Update specifically flagging acute pancreatitis as an infrequent but serious risk with GLP-1 medicines, the symptom profile of pancreatitis can overlap with ordinary nausea at first, and the distinction matters. The MHRA's Yellow Card scheme lets patients and prescribers report suspected side effects, which helps regulators track patterns across the whole population using these medicines.
If your nausea is persistent rather than acute, the right conversation is with your prescriber. They can consider whether the dose schedule needs adjusting, whether a slower titration makes sense, or whether there are other factors at play. Our practical guide to managing nausea on Mounjaro covers the evidence-based strategies in more detail. For those wondering whether the sick feeling differs between Mounjaro and the semaglutide injections, nausea profiles across GLP-1 and dual-agonist medicines explains what the trials show.
If you are considering Mounjaro and nausea is a concern before you even begin, it helps to know what the realistic trajectory looks like. The side-effect profile is front-loaded: the first few weeks at each dose are the most likely time to feel unwell, and many people report the experience is notably milder than they expected based on what they had read online.
When a pen is dispensed through a regulated UK pharmacy, it arrives the next working day in plain packaging with a DPD tracking notification, you know exactly when to expect it. But what comes with the pen matters as much as the pen itself: at nume, every patient has access to prescriber support seven days a week, which is specifically useful in those early weeks when questions about side effects tend to come up. If you are also curious about the cost side of starting treatment, the context around Eli Lilly's UK price changes is worth understanding before you compare providers.
The pattern of nausea in the hours after an injection is a related question that comes up often, and one our prescribers hear regularly in the days following a first dose. Worth reading if you want to plan ahead.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.